Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
Tabla de Políticas Médicas
| ID | Título | Revisión | Descripción | Acceso |
|---|---|---|---|---|
| 05.001.038 | Erythropoiesis-Stimulating Agents | Nov 2025 | Endogenous erythropoietin is a glycoprotein hematopoietic growth factor that regulates hemoglobin levels in... | Ver |
| 05.001.039 | Intravenous Antibiotic Therapy And Associated Diagnostic Testing For Lyme Disease | Nov 2025 | Lyme disease is a multisystem inflammatory disease caused by the spirochete borrelia burgdorferi and... | Ver |
| 05.001.040 | Repository Corticotropin Injection | Nov 2025 | Repository corticotropin injection is a preparation of the natural form of adrenocorticotropic hormone... | Ver |
| 05.001.041 | Injectable Clostridial Collagenase For Fibroproliferative Disorders | Apr 2026 | Clostridial collagenase is a bacterial collagenase, derived from clostridium histolyticum, which has been... | Ver |
| 05.001.042 | Esketamine Nasal Spray For Treatment-Resistant Depression | Jan 2026 | Esketamine is the s-isomer of racemic ketamine. esketamine targets the n-methyl-d-aspartate receptor, an... | Ver |
| 05.001.043 | Hematopoietic Colony-Stimulating Factors (Csfs) | Sep 2025 | Hematopoietic colony-stimulating factors (csfs) are biologic agents used to stimulate the production of... | Ver |
| 05.001.044 | Polivy® (polatuzumab vedotin-piiq) | Sep 2025 | Polivy® (polatuzumab vedotin-piiq) is an antibody-drug conjugate directed against cd79b. it is... | Ver |
| 05.001.045 | Lumasiran For Primary Hyperoxaluria Type 1 | Aug 2025 | Primary hyperoxalurias are a group of rare genetic diseases. there are 3 subtypes each resulting in the... | Ver |
| 05.001.046 | Monoclonal Antibodies for Treatment of Alzheimer Disease | Mar 2026 | Alzheimer disease (ad) is a neurodegenerative disorder leading to progressive, irreversible destruction of... | Ver |
| 05.001.047 | Fibrin Sealant | Sep 2025 | ... | Ver |
| 05.001.048 | Biological Treatments for Refractory Myasthenia Gravis | Mar 2026 | Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness... | Ver |
| 05.001.049 | Givosiran for Acute Hepatic Porphyria | Oct 2025 | Acute hepatic porphyria (ahp) is a rare disease with a prevalence of 5 to 10 cases/100,000 people in the us... | Ver |
| 05.001.050 | Omidubicel as Adjunct Treatment for Hematologic Malignancies | Oct 2025 | Hematologic malignancies are a heterogeneous group of diseases characterized by distinct biological subtypes,... | Ver |
| 05.001.051 | Pharmacologic Treatments for Metabolic Dysfunction-Associated Steatohepatitis | Nov 2025 | Metabolic dysfunction-associated steatohepatitis (mash), formerly known as non-alcoholic steatohepatitis... | Ver |
| 05.001.052 | Tofersen (Qalsody) | Sep 2025 | Tofersen (qalsody) is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral... | Ver |
| 05.001.053 | Mitotic Inhibitors | Sep 2025 | Mitotic inhibitors (paclitaxel, docetaxel, abraxane) are chemotherapy agents used in multiple solid tumors,... | Ver |
| 05.001.054 | Denosumab Products and its biosimilars | May 2026 | Denosumab is a fully human monoclonal antibody against receptor activator of nuclear factor κ-β... | Ver |
| 05.002.001 | Chimeric Antigen Receptor Therapy for Multiple Myeloma | Mar 2026 | Multiple myeloma is a hematologic malignancy characterized by abnormal growth of plasma cells with production... | Ver |
| 05.003.001 | Gene Therapies for Thalassemia | Apr 2026 | Beta (β)-thalassemia is a genetic hemoglobinopathy that results from defects in β-globin synthesis... | Ver |
| 05.003.002 | Gene Therapies for Sickle Cell Disease | Apr 2026 | Sickle cell disease is a genetic hemoglobinopathy that results from a genetic variant in the hbb gene... | Ver |